Medivation's (NASDAQ: MDVN) Phase II ABRAZO trial with talazoparib in metastatic gBRCA mutant breast cancer patients was closed for enrollment before it reached its target, to allow focus on the ongoing Phase III EMBRACA trial, said an investigator.
The target enrollment for ABRAZO was 140 patients, according to ClinicaTrials.gov. BioMarin (NASDAQ:BMRN), the previous owner of talazoparib, announced 20 July 2015 a cohort expansion for ABRAZO from 70 to 140 patients. Medivation acquired the worldwide rights for talazoparib from Biomarin (NASDAQ:BMRN) in August 2015 for an upfront cost of USD 410m and additional milestone-based payments of USD 160m.
A number of PARP inhibitors are being studied in the metastatic breast cancer setting including talazoparib, AstraZeneca's (LON:AZN) Lynparza (olaparib), Clovis Oncology's (NASDAQ:CLVS) rucaparib, Tesaro's (NASDAQ:TSRO) niraparib and AbbVie's (NYSE:ABBV) veliparib. Lynparza was the first and is currently the only approved PARP inhibitor indicated as a fourth-line treatment in ovarian cancer patients with BRCA mutation.
Global sales for Lynparza are estimated to be USD 623.5m in 2020 and USD 450m for breast cancer alone, according to BioPharm Insight's (BPI) consensus of seven analyst reports, while those for talazoparib are expected to be USD 275m in 2025, according to BPI research.